Research suggests that selenium may influence the behavior of the cancer risk in two ways. As an antioxidant, selenium helps to protect the body against free radicals. Selenium may also prevent or slow tumor growth, as some breakdown products of selenium can inhibit tumor growth by enhancing immune cell activity and inhibition of tumor blood vessel development.
The aim of this study was to determine the level of selenium in blood serum as a potential marker of risk for cancers of the colon, stomach or pancreas.
Material and methods
The research material was a total of 94 samples of blood serum from people with cancer, diagnosed and confirmed in one of the organs: colon (55 cases), pancreas (30 cases) or stomach (9 cases) and 94 samples of blood serum derived from healthy individuals which paired control group. The criteria adopted for pairing included: gender, year of birth (+/- 3 years), history of the occurrence of cancers in the family among first degree relatives and smoking status expressed in pack-years.
Selenium concentration in blood plasma was determined using graphite furnace atomic absorption spectrometry (GFAAS). The measurement accuracy was +/- 5% µg Se/l.
The obtained results suggest that low levels of selenium in the body may correlate with an increased risk of pancreatic cancer, colon or stomach, and thus constitute one of the markers of risk for cancers of such sites. Research requires the extension to a larger number of samples including tumor size, and performance analysis for selenoprotein genes.
Prospective studies can elucidate:
a) the use of selenium measurements as markers of risk of above cancers;
b) possibility of lowering risk of the cancers of the colon, pancreas and stomach by supplementation of diet with selenium.